<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02927834</url>
  </required_header>
  <id_info>
    <org_study_id>5130196</org_study_id>
    <nct_id>NCT02927834</nct_id>
  </id_info>
  <brief_title>Oral Steroids in Chronic Rhinosinusitis Without Nasal Polyps</brief_title>
  <official_title>The Role of Oral Steroids in the Management of Chronic Rhinosinusitis Without Nasal Polyps</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic rhinosinusitis is a common disease that effects millions of people world wide.&#xD;
      Despite its frequency it is unclear what treatment options are the best for these patients.&#xD;
      Typically patients with chronic rhinosinusitis without nasal polyps (CRSsNP) are given a long&#xD;
      term antibiotic (3 weeks), nasal steroid sprays, saline nasal irrigation and occasionally&#xD;
      oral steroids. Oral steroids benefit patients with chronic rhinosinusitis with nasal polyps&#xD;
      (CRSwNP) however their role in non polyp patients is less clear. It is the goal of this study&#xD;
      to see if oral steroids benefit the treatment outcomes in those patients with chronic&#xD;
      rhinosinusitis without nasal polyps. In addition this study will look to see if a short&#xD;
      course (5 day burst) versus a longer course (21 day taper) of oral steroids make a difference&#xD;
      in outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will compare patients with CRSsNP who are treated with antibiotics/nasal&#xD;
      steroid sprays, and compare them to chronic sinusitis patients who receive antibiotics/nasal&#xD;
      steroid spray along with a course of oral steroids. The goal is to determine if oral steroids&#xD;
      have a role in CRSsNP, and if so, the most effective dosage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sinonasal Outcome Test (SNOT 20)</measure>
    <time_frame>4 weeks post treatment</time_frame>
    <description>Sinonasal outcome test to access nasal/sinus symptoms. 20 questions, each question scored 0-5. 0 meaning no symptoms, 5 worse. 0- 100 total with lower number meaning better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nasal Endoscopy</measure>
    <time_frame>4 weeks post treatment</time_frame>
    <description>Physical exam findings of the nasal cavity. Scored 0-12. Lower score is better</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CT Scan Changes</measure>
    <time_frame>4 week post treatment</time_frame>
    <description>CT scan of the sinuses, Lund Mackay score to access severity of sinus disease on CT scan. Scored on scale 0-20 with lower score better.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Sinusitis</condition>
  <arm_group>
    <arm_group_label>Antibiotic only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1. Augmentin (amoxicillin/clavulanate 875/125mg) orally (PO) twice a day for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Augmentin with 6 day steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Augmentin with 6 day prednisone taper (40mg PO daily (QD) for 2 days, 20mg PO QD for 2 days, 10mg PO QD for 2 days, then stop)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Augmentin with 21 day steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Augmentin with 21 days prednisone taper (40mg PO QD for 5 days, 30mg PO QD for 5 days, 20mg PO QD for 5 days, 10mg PO QD for 5 days, then stop. )</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6 day Prednisone</intervention_name>
    <description>6 day prednisone burst</description>
    <arm_group_label>Augmentin with 6 day steroid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Augmentin</intervention_name>
    <description>Antibiotic augmentin for 3 weeks</description>
    <arm_group_label>Antibiotic only</arm_group_label>
    <arm_group_label>Augmentin with 21 day steroid</arm_group_label>
    <arm_group_label>Augmentin with 6 day steroid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>21 day Prednisone</intervention_name>
    <description>21 day prednisone burst</description>
    <arm_group_label>Augmentin with 21 day steroid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. They have three-months of persistent symptoms meeting criteria for chronic&#xD;
             rhinosinusitis as defined by the taskforce on rhinosinusitis.&#xD;
&#xD;
          2. They have a CT-scan in the clinic or have a viewable recent (&lt; 3 weeks prior to clinic&#xD;
             visit) CT-scan with a Lund Mackay score of 6 or greater. A Lund Mackay score of 6 or&#xD;
             greater is felt to be indicative of at least moderate CRS.&#xD;
&#xD;
          3. They do not have nasal polyps on initial clinic nasal endoscopy&#xD;
&#xD;
          4. They are willing to participate in a clinical study&#xD;
&#xD;
          5. They are between the ages of 18 to 80.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. They have a condition in which the use of systemic corticosteroids is contraindicated&#xD;
             such as diabetes will be excluded.&#xD;
&#xD;
          2. They are unable to or unwilling to take the prescribed antibiotics or steroids will&#xD;
             excluded.&#xD;
&#xD;
          3. They have been treated with a &gt; 3 week course of antibiotics and/or systemic steroids&#xD;
             will also be excluded.&#xD;
&#xD;
          4. They have variants of chronic sinusitis known to be refractory to medical therapy such&#xD;
             as Wegener's granulomatosis, primary ciliary dyskinesia or sarcoidosis.&#xD;
&#xD;
          5. They have sinusitis secondary to prior surgery, a dental procedure or anatomical&#xD;
             variants.&#xD;
&#xD;
          6. They have nasal polyps on physical exam.&#xD;
&#xD;
          7. They are pregnant. Subjects who are possibly pregnant will be excluded based on&#xD;
             history. Pregnancy testing is not standard of care for diagnostic imaging.&#xD;
&#xD;
          8. They have a Lund-Mackay score on CT scan of &lt; 6&#xD;
&#xD;
          9. They are &lt; 18 or &gt; 80 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>October 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2016</study_first_posted>
  <results_first_submitted>October 9, 2020</results_first_submitted>
  <results_first_submitted_qc>December 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 29, 2020</results_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Kristin Seiberling, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 3, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT02927834/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Antibiotic Only</title>
          <description>1. Augmentin (amoxicillin/clavulanate 875/125mg) orally (PO) twice a day for 3 weeks.&#xD;
Augmentin: Antibiotic augmentin for 3 weeks</description>
        </group>
        <group group_id="P2">
          <title>Augmentin With 6 Day Steroid</title>
          <description>Augmentin with 6 day prednisone taper (40mg PO daily (QD) for 2 days, 20mg PO QD for 2 days, 10mg PO QD for 2 days, then stop)&#xD;
6 day Prednisone: 6 day prednisone burst&#xD;
Augmentin: Antibiotic augmentin for 3 weeks</description>
        </group>
        <group group_id="P3">
          <title>Augmentin With 21 Day Steroid</title>
          <description>Augmentin with 21 days prednisone taper (40mg PO QD for 5 days, 30mg PO QD for 5 days, 20mg PO QD for 5 days, 10mg PO QD for 5 days, then stop. )&#xD;
Augmentin: Antibiotic augmentin for 3 weeks&#xD;
21 day Prednisone: 21 day prednisone burst</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Antibiotic Only</title>
          <description>1. Augmentin (amoxicillin/clavulanate 875/125mg) orally (PO) twice a day for 3 weeks.&#xD;
Augmentin: Antibiotic augmentin for 3 weeks</description>
        </group>
        <group group_id="B2">
          <title>Augmentin With 6 Day Steroid</title>
          <description>Augmentin with 6 day prednisone taper (40mg PO daily (QD) for 2 days, 20mg PO QD for 2 days, 10mg PO QD for 2 days, then stop)&#xD;
6 day Prednisone: 6 day prednisone burst&#xD;
Augmentin: Antibiotic augmentin for 3 weeks</description>
        </group>
        <group group_id="B3">
          <title>Augmentin With 21 Day Steroid</title>
          <description>Augmentin with 21 days prednisone taper (40mg PO QD for 5 days, 30mg PO QD for 5 days, 20mg PO QD for 5 days, 10mg PO QD for 5 days, then stop. )&#xD;
Augmentin: Antibiotic augmentin for 3 weeks&#xD;
21 day Prednisone: 21 day prednisone burst</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.28" spread="1"/>
                    <measurement group_id="B2" value="58.5" spread="1"/>
                    <measurement group_id="B3" value="41.2" spread="1"/>
                    <measurement group_id="B4" value="50.8" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sinonasal Outcome Test (SNOT 20)</title>
        <description>Sinonasal outcome test to access nasal/sinus symptoms. 20 questions, each question scored 0-5. 0 meaning no symptoms, 5 worse. 0- 100 total with lower number meaning better outcome</description>
        <time_frame>4 weeks post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antibiotic Only</title>
            <description>1. Augmentin (amoxicillin/clavulanate 875/125mg) orally (PO) twice a day for 3 weeks.&#xD;
Augmentin: Antibiotic augmentin for 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Augmentin With 6 Day Steroid</title>
            <description>Augmentin with 6 day prednisone taper (40mg PO daily (QD) for 2 days, 20mg PO QD for 2 days, 10mg PO QD for 2 days, then stop)&#xD;
6 day Prednisone: 6 day prednisone burst&#xD;
Augmentin: Antibiotic augmentin for 3 weeks</description>
          </group>
          <group group_id="O3">
            <title>Augmentin With 21 Day Steroid</title>
            <description>Augmentin with 21 days prednisone taper (40mg PO QD for 5 days, 30mg PO QD for 5 days, 20mg PO QD for 5 days, 10mg PO QD for 5 days, then stop. )&#xD;
Augmentin: Antibiotic augmentin for 3 weeks&#xD;
21 day Prednisone: 21 day prednisone burst</description>
          </group>
        </group_list>
        <measure>
          <title>Sinonasal Outcome Test (SNOT 20)</title>
          <description>Sinonasal outcome test to access nasal/sinus symptoms. 20 questions, each question scored 0-5. 0 meaning no symptoms, 5 worse. 0- 100 total with lower number meaning better outcome</description>
          <units>Score out of total 100</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.33" lower_limit="-2.21" upper_limit="56.29"/>
                    <measurement group_id="O2" value="53.14" lower_limit="1.79" upper_limit="59.92"/>
                    <measurement group_id="O3" value="37" lower_limit="2.85" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nasal Endoscopy</title>
        <description>Physical exam findings of the nasal cavity. Scored 0-12. Lower score is better</description>
        <time_frame>4 weeks post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antibiotic Only</title>
            <description>1. Augmentin (amoxicillin/clavulanate 875/125mg) orally (PO) twice a day for 3 weeks.&#xD;
Augmentin: Antibiotic augmentin for 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Augmentin With 6 Day Steroid</title>
            <description>Augmentin with 6 day prednisone taper (40mg PO daily (QD) for 2 days, 20mg PO QD for 2 days, 10mg PO QD for 2 days, then stop)&#xD;
6 day Prednisone: 6 day prednisone burst&#xD;
Augmentin: Antibiotic augmentin for 3 weeks</description>
          </group>
          <group group_id="O3">
            <title>Augmentin With 21 Day Steroid</title>
            <description>Augmentin with 21 days prednisone taper (40mg PO QD for 5 days, 30mg PO QD for 5 days, 20mg PO QD for 5 days, 10mg PO QD for 5 days, then stop. )&#xD;
Augmentin: Antibiotic augmentin for 3 weeks&#xD;
21 day Prednisone: 21 day prednisone burst</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Endoscopy</title>
          <description>Physical exam findings of the nasal cavity. Scored 0-12. Lower score is better</description>
          <units>score out of total 12</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" lower_limit="-2.197" upper_limit="2.974"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.793" upper_limit="3.492"/>
                    <measurement group_id="O3" value="2.16" lower_limit="-2.37" upper_limit="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CT Scan Changes</title>
        <description>CT scan of the sinuses, Lund Mackay score to access severity of sinus disease on CT scan. Scored on scale 0-20 with lower score better.</description>
        <time_frame>4 week post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antibiotic Only</title>
            <description>1. Augmentin (amoxicillin/clavulanate 875/125mg) orally (PO) twice a day for 3 weeks.&#xD;
Augmentin: Antibiotic augmentin for 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Augmentin With 6 Day Steroid</title>
            <description>Augmentin with 6 day prednisone taper (40mg PO daily (QD) for 2 days, 20mg PO QD for 2 days, 10mg PO QD for 2 days, then stop)&#xD;
6 day Prednisone: 6 day prednisone burst&#xD;
Augmentin: Antibiotic augmentin for 3 weeks</description>
          </group>
          <group group_id="O3">
            <title>Augmentin With 21 Day Steroid</title>
            <description>Augmentin with 21 days prednisone taper (40mg PO QD for 5 days, 30mg PO QD for 5 days, 20mg PO QD for 5 days, 10mg PO QD for 5 days, then stop. )&#xD;
Augmentin: Antibiotic augmentin for 3 weeks&#xD;
21 day Prednisone: 21 day prednisone burst</description>
          </group>
        </group_list>
        <measure>
          <title>CT Scan Changes</title>
          <description>CT scan of the sinuses, Lund Mackay score to access severity of sinus disease on CT scan. Scored on scale 0-20 with lower score better.</description>
          <units>score out of total 20</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.33" lower_limit="8.15" upper_limit="11.3"/>
                    <measurement group_id="O2" value="11" lower_limit="7.68" upper_limit="11.8"/>
                    <measurement group_id="O3" value="11.83" lower_limit="5.13" upper_limit="13.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Patients were seen back in the office for adverse event collection</desc>
      <group_list>
        <group group_id="E1">
          <title>Antibiotic Only</title>
          <description>1. Augmentin (amoxicillin/clavulanate 875/125mg) orally (PO) twice a day for 3 weeks.&#xD;
Augmentin: Antibiotic augmentin for 3 weeks</description>
        </group>
        <group group_id="E2">
          <title>Augmentin With 6 Day Steroid</title>
          <description>Augmentin with 6 day prednisone taper (40mg PO daily (QD) for 2 days, 20mg PO QD for 2 days, 10mg PO QD for 2 days, then stop)&#xD;
6 day Prednisone: 6 day prednisone burst&#xD;
Augmentin: Antibiotic augmentin for 3 weeks</description>
        </group>
        <group group_id="E3">
          <title>Augmentin With 21 Day Steroid</title>
          <description>Augmentin with 21 days prednisone taper (40mg PO QD for 5 days, 30mg PO QD for 5 days, 20mg PO QD for 5 days, 10mg PO QD for 5 days, then stop. )&#xD;
Augmentin: Antibiotic augmentin for 3 weeks&#xD;
21 day Prednisone: 21 day prednisone burst</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kristin Seiberling</name_or_title>
      <organization>Loma Linda University</organization>
      <phone>9095582002</phone>
      <email>kseiberling@llu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

